Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) has shared an update.
On April 23, 2026, Tonix Pharmaceuticals reported data presentations from the American Association for Cancer Research Annual Meeting 2026, held April 17-22, 2026, highlighting preclinical progress for its oncology pipeline. Collaborators from Columbia University presented results showing that declining TFF2 in aged mice drives IL-1β–mediated gastric inflammaging and tumor susceptibility, with the murine version of TNX-1700 reversing aging-associated inflammation and attenuating tumor progression in this model.
Tonix also presented in vitro work on fully human antagonistic anti-BTLA monoclonal antibodies, part of its TNX-4700 cancer program, indicating high affinity, cross-reactivity and Fc-engineering designed to improve pharmacokinetics and reduce Fc receptor–related toxicities. A second poster on TNX-1700 pharmacokinetics in non-human primates and humanized mice showed linear, dose-independent exposure and extended TFF2 half-life without significant toxicity, reinforcing TNX-1700’s potential as a therapeutic candidate in gastric and colorectal cancer when combined with PD-1 blockade.
The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
The score is held down primarily by weak financial performance (large ongoing operating losses and persistent cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate events provide support via encouraging clinical/pipeline progress and the Nasdaq uplisting, but valuation remains constrained by negative earnings and no dividend.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company developing product candidates in immunology and oncology, including biologic therapies for gastric and colorectal cancers. Its pipeline features agents such as TNX-1700, targeting mechanisms of tumor-associated inflammation, and TNX-4700, an anti-BTLA monoclonal antibody program aimed at enhancing cancer immunotherapy responses.
Average Trading Volume: 403,378
Technical Sentiment Signal: Sell
Current Market Cap: $181.1M
See more data about TNXP stock on TipRanks’ Stock Analysis page.